References
- 1. Spasovski GB. Bone health and vascular calcification relationships in chronic kidney disease. Int Urol Nephrol. 2007; 39:1209-16.17899431
- 2. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3):S1-201.
- 3. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKDMBD). Kidney Int Suppl. 2009; 113:S1-130.
- 4. Hutchison AJ, Smith CP, Brenchley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol. 2011; 7:578-89.10.1038/nrneph.2011.112
- 5. D’Haese PC, De Broe M. Aluminum, Lanthanum, and Strontium. Fourth ed: Lippincott Williams & Wilkins; 2006.
- 6. Kausz AT, Antonsen JE, Hercz G, Pei Y, Weiss NS, Emerson S, et al. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am J Kidney Dis. 1999; 34:688-93.10.1016/S0272-6386(99)70394-X
- 7. Cannata-Andia JB, Fernandez-Martin JL. The clinical impact of aluminium overload in renal failure. Nephrol Dial Transplant. 2002; 17 Suppl 2:9-12.
- 8. Jaffe JA, Liftman C, Glickman JD. Frequency of elevated serum aluminum levels in adult dialysis patients. Am J Kidney Dis. 2005; 46:316-9.10.1053/j.ajkd.2005.04.020
- 9. Malluche HH. Aluminium and bone disease in chronic renal failure. Nephrol Dial Transplant. 2002; 17 Suppl 2:21-4.
- 10. D’Haese PC, Couttenye MM, Goodman WG, Lemoniatou E, Digenis P, Sotornik I, et al. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. Nephrol Dial Transplant. 1995; 10:1874-84.
- 11. D’Haese PC, Couttenye MM, De Broe ME. Diagnosis and treatment of aluminium bone disease. Nephrol Dial Transplant. 1996; 11 Suppl 3:74-9.
- 12. Urena P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol. 1996; 7:506-12.
- 13. Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int. 1999; 55:2141-56.10.1046/j.1523-1755.1999.00461.x
- 14. Roe S, Cassidy MJ. Diagnosis and monitoring of renal osteodystrophy. Curr Opin Nephrol Hypertens. 2000; 9:675-81.
- 15. Morishita T, Nomura M, Hanaoka M, Saruta T, Matsuo T, Tsukamoto Y. A new assay method that detects only intact osteocalcin. Two-step non-invasive diagnosis to predict adynamic bone disease in haemodialysed patients. Nephrol Dial Transplant. 2000; 15:659-67.
- 16. Ferreira A, Drueke TB. Biological markers in the diagnosis of the different forms of renal osteodystrophy. Am J Med Sci. 2000; 320:85-9.10.1097/00000441-200008000-00004
- 17. Bervoets AR, Spasovski GB, Behets GJ, Dams G, Polenakovic MH, Zafirovska K, et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis. 2003; 41:997-1007.10.1016/S0272-6386(03)00197-5
- 18. Ferreira A. Development of renal bone disease. Eur J Clin Invest. 2006; 36 Suppl 2:2-12.10.1111/j.1365-2362.2006.01661.x
- 19. Schwarz C, Sulzbacher I, Oberbauer R. Diagnosis of renal osteodystrophy. Eur J Clin Invest. 2006; 36 Suppl 2:13-22.10.1111/j.1365-2362.2006.01666.x
- 20. Hamano T, Tomida K, Mikami S, Matsui I, Fujii N, Imai E, et al. Usefulness of bone resorption markers in hemodialysis patients. Bone. Jul 2009;45 Suppl 1: S19-25.10.1016/j.bone.2009.03.663
- 21. Mudge DW, Johnson DW, Hawley CM, Campbell SB, Isbel NM, van Eps CL, et al. Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol. 2011; 12:2010.1186/1471-2369-12-20
- 22. Gault PM, Allen KR, Newton KE. Plasma aluminium: a redundant test for patients on dialysis? Ann Clin Biochem. 2005; 42:51-4.10.1258/0004563053026862
- 23. Arenas MD, Malek T, Gil MT, Moledous A, Nunez C, Alvarez-Ude F. Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era. Nefrologia. 2008; 28:168-73.
- 24. Pepper R, Campbell N, Yaqoob MM, Roberts NB, Fan SL. Do oral aluminium phosphate binders cause accumulation of aluminium to toxic levels? BMC Nephrol. 2011; 12:55.10.1186/1471-2369-12-55
- 25. Kan WC, Chien CC, Wu CC, Su SB, Hwang JC, Wang HY. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients. Nephrol Dial Transplant. 2010; 25:1604-8.
- 26. Bellows CG, Heersche JN, Aubin JE. Aluminum accelerates osteoblastic differentiation but is cytotoxic in long-term rat calvaria cell cultures. Calcif Tissue Int. 1999; 65:59-65.10.1007/s002239900658